Satoreotide Tetraxetan features a somatostatin-analog peptide linked to a tetraxetan chelator suitable for radiometal coordination studies. Cyclic backbone constraints promote defined receptor-binding conformations. Researchers investigate its metal-loading behavior, stability, and stereochemical preferences. Use spans receptor-ligand modeling, coordination chemistry, and radiometal-chelate optimization in preclinical systems.
CAT No: R2539
CAS No:1039726-31-2
Synonyms/Alias:DOTA satoreotide;Satoreotide DOTA;Satoreotide tetraxetan;EC1O2FB9FV;DOTA-JR-11;1039726-31-2;UNII-EC1O2FB9FV;DOTA-JR11;satoreotida tetraxetan;SATOREOTIDE TETRAXETAN [INN];D-TYROSINAMIDE, 4-CHLORO-N-(2-(4,7,10-TRIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL)ACETYL)-L-PHENYLALANYL-D-CYSTEINYL-4-((((4S)-HEXAHYDRO-2,6-DIOXO-4-PYRIMIDINYL)CARBONYL)AMINO)-L-PHENYLALANYL-4-((AMINOCARBONYL)AMINO)-D-PHENYLALANYL-L-LYSYL-L-THREONYL-L-CYSTEINYL-, CYCLIC (2->7)-DISULFIDE;satoreotidum tetraxetanum;CHEMBL4297531;EX-A5520;HY-P5128;DA-63000;CS-0775089;
Satoreotide Tetraxetan is a synthetic peptide conjugate designed for advanced research applications in molecular imaging and targeted radiopharmaceutical development. As a somatostatin receptor (SSTR) antagonist peptide complexed with the chelator tetraxetan, it is notable for its high affinity and selectivity towards somatostatin receptor subtypes, particularly SSTR2. The conjugation of the tetraxetan moiety enables stable chelation of radiometals, making the compound particularly valuable for studies involving radiolabeling and receptor-targeted detection. Its biochemical architecture and receptor-binding properties have positioned it as a sophisticated tool for investigating receptor biology, ligand-receptor interactions, and the development of novel targeted agents.
Radiolabeling Research: In the context of radiopharmaceutical development, the peptide-chelator structure of Satoreotide Tetraxetan facilitates efficient and stable complexation with a variety of medically relevant radiometals, such as lutetium-177 or gallium-68. Researchers employ this compound to study the optimization of radiolabeling protocols, evaluate chelation stability, and assess radiochemical yields. These investigations are essential for developing new radiolabeled probes for preclinical imaging and biodistribution studies, supporting the advancement of targeted imaging agents.
Somatostatin Receptor Targeting Studies: The high receptor affinity and antagonist profile of this peptide make it an important tool for exploring somatostatin receptor pharmacology. By selectively binding to SSTR2 and related subtypes, Satoreotide Tetraxetan enables the detailed study of receptor-ligand interactions, receptor density mapping, and internalization dynamics. Such work underpins the rational design of next-generation somatostatin receptor-targeted compounds and contributes to a deeper understanding of receptor-mediated cellular signaling pathways.
Peptide-Drug Conjugate Development: The modular nature of Satoreotide Tetraxetan, combining a targeting peptide with a versatile chelator, renders it useful for the design and evaluation of peptide-drug conjugates (PDCs). Researchers utilize the compound as a model scaffold to investigate strategies for site-specific conjugation, linker stability, and payload delivery to SSTR-expressing cells. These studies inform the development of targeted delivery systems for imaging or therapeutic payloads in experimental settings.
Pharmacokinetic and Biodistribution Profiling: The unique receptor-targeting and radiolabeling capabilities of this peptide conjugate enable comprehensive pharmacokinetic and biodistribution studies in preclinical models. By tracking the in vivo distribution of radiolabeled conjugates, researchers can assess tissue uptake, clearance rates, and receptor-mediated localization. These insights are critical for optimizing the design of targeted agents and for predicting their behavior in complex biological systems.
Analytical Method Development: Satoreotide Tetraxetan serves as a robust reference compound for the development and validation of analytical methods in peptide radiochemistry and receptor binding assays. Its defined structure and receptor specificity allow for the calibration of chromatographic techniques, mass spectrometry protocols, and radiolabeling efficiency tests. These analytical applications support quality control, method standardization, and reproducibility in research workflows centered on peptide-based radiopharmaceuticals and receptor-targeted agents.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More